RenaZorb is a small molecule commercialized by Unicycive Therapeutics, with a leading Phase III program in Hyperphosphatemia In Chronic Kidney Disease. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of RenaZorb’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for RenaZorb is expected to reach an annual total of $308 mn by 2026 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RenaZorb (SPI-014) is under development for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) and chronic kidney disease (CKD). The drug candidate is administered orally as a tablet. It is a second-generation lanthanum-based compound (lanthanum dioxycarbonate) targeting phosphate ions. The drug candidate is developed based on nanoparticle technology.
Unicycive Therapeutics Overview
Unicycive Therapeutics is a biotechnology company that develops novel treatments across multiple therapeutic areas. The company’s pipeline program include Renazor targeting hyperphosphatemia; UNI-494 for the treatment of acute kidney injury; and others. Unicycive Therapeutics is headquartered in Los Altos, California, the US.
The company reported revenues of (US Dollars) US$1 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$18.1 million in FY2022, compared to an operating loss of US$9 million in FY2021. The net loss of the company was US$18.1 million in FY2022, compared to a net loss of US$10 million in FY2021.
For a complete picture of RenaZorb’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.